FULCRUM THERAPEUTICS INC (FULC)

US3596161097 - Common Stock

4.35  +0.32 (+7.94%)

After market: 4.35 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031
Revenue
YoY % growth
19.16M
117.23%
6.34M
-66.91%
2.805M
-55.76%
81.921M
2,820.53%

-100.00%
44.377M
-100.00%
4.959M26.59M
436.20%
81.754M
207.46%
145.32M
77.75%
EBITDA
YoY % growth
-78.53M
-13.43%
-109.72M
-39.72%
-108.492M
1.12%
-20.107M
81.47%
-82.95M
-312.55%
-65.18M
21.42%
N/AN/AN/AN/AN/A
EBIT
YoY % growth
-81.05M
-13.18%
-112.13M
-38.35%
-110.664M
1.31%
-24.962M
77.44%
-91.933M
-268.29%
-102.201M
-11.17%
-81.044M
20.70%
-76.895M
5.12%
-56.349M
26.72%
-3.993M
92.91%
56.042M
1,503.40%
Operating Margin
-423.02%-1,768.61%-3,945.24%-30.47%N/A-230.30%N/A-1,550.61%-211.92%-4.88%38.56%
EPS
YoY % growth
-2.29
18.51%
-2.48
-8.30%
-1.58
36.29%
-0.24
84.67%
-1.27
-422.57%
-1.40
-10.50%
-0.97
30.36%
-0.89
8.38%
-0.61
31.43%
-0.02
96.67%
0.61
3,100.00%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth
-0.32
19.82%
-0.33
22.51%
-0.33
-138.10%
-0.34
2.37%
-0.35
-8.76%
Revenue
Q2Q % growth

-100.00%

-100.00%
EBITDA
Q2Q % growth
-20.002M
22.53%
N/AN/AN/AN/A
EBIT
Q2Q % growth
-22.272M
20.44%
-22.87M
23.34%
-22.81M
-143.45%
-23.379M
-1.37%
-23.728M
-6.54%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth
-0.35
10.26%
-0.410.0615.39%
Q2 2024
Q2Q % growth
0.87
328.95%
-0.010.886,923.53%
Q1 2024
Q2Q % growth
-0.43
-4.88%
-0.450.023.64%
Q4 2023
Q2Q % growth
-0.40
20.00%
-0.430.037.88%
Q3 2023
Q2Q % growth
-0.39
23.53%
-0.440.0512.10%
Q2 2023
Q2Q % growth
-0.38
54.22%
-0.450.0716.20%
Q1 2023
Q2Q % growth
-0.41
35.94%
-0.460.0511.75%
Q4 2022
Q2Q % growth
-0.50
13.79%
-0.500.00-0.06%
Q3 2022
Q2Q % growth
-0.51
10.53%
-0.620.1118.32%
Q2 2022
Q2Q % growth
-0.83
-38.33%
-0.67-0.16-23.17%
Q1 2022
Q2Q % growth
-0.64
-18.52%
-0.640.00-0.11%
Q4 2021
Q2Q % growth
-0.58
9.38%
-0.740.1621.83%
Q3 2021
Q2Q % growth
-0.57
18.57%
-0.660.0913.59%
Q2 2021
Q2Q % growth
-0.60
9.09%
-0.640.045.81%
Q1 2021
Q2Q % growth
-0.54
33.33%
-0.670.1319.42%
Q4 2020
Q2Q % growth
-0.64
9.86%
-0.740.1013.46%
Q3 2020
Q2Q % growth
-0.70
27.84%
-0.67-0.03-5.04%
Q2 2020
Q2Q % growth
-0.66
92.83%
-0.790.1316.62%
Q1 2020
Q2Q % growth
-0.81 -0.77-0.04-5.41%
Q4 2019
Q2Q % growth
-0.71 -0.850.1416.64%
Q3 2019
Q2Q % growth
-0.97 -3.042.0768.06%
Q2 2019
Q2Q % growth
-9.21 -3.16-6.05-191.27%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth

-100.00%
%
Q2 2024
Q2Q % growth
80M
8,990.91%
37.276M42.724M114.62%
Q1 2024
Q2Q % growth

-100.00%
367.343K-367.343K-100.00%
Q4 2023
Q2Q % growth
871K
26.23%
470.393K400.607K85.16%
Q3 2023
Q2Q % growth
759K
-35.68%
1.073M-314K-29.26%
Q2 2023
Q2Q % growth
880K
-53.19%
1.138M-258K-22.67%
Q1 2023
Q2Q % growth
295K
-88.61%
1.15M-855K-74.35%
Q4 2022
Q2Q % growth
690K
-86.36%
1.687M-997K-59.10%
Q3 2022
Q2Q % growth
1.18M
-76.11%
2.594M-1.414M-54.51%
Q2 2022
Q2Q % growth
1.88M
-57.08%
3.024M-1.144M-37.83%
Q1 2022
Q2Q % growth
2.59M
-45.93%
4.023M-1.433M-35.62%
Q4 2021
Q2Q % growth
5.06M
19.62%
2.733M2.327M85.14%
Q3 2021
Q2Q % growth
4.94M
167.03%
2.295M2.645M115.25%
Q2 2021
Q2Q % growth
4.38M
119.00%
1.629M2.751M168.88%
Q1 2021
Q2Q % growth
4.79M
538.67%
1.454M3.336M229.44%
Q4 2020
Q2Q % growth
4.23M 1.332M2.898M217.57%
Q3 2020
Q2Q % growth
1.85M 561K1.289M229.77%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS30.51% 30.51% 14.84% 37.5%
Revenue-100% -100% -0.05% -8.09%